• No results found

Knowledge and Attitude about Exposure to Cytotoxic Drugs in Oncology Nurses

N/A
N/A
Protected

Academic year: 2020

Share "Knowledge and Attitude about Exposure to Cytotoxic Drugs in Oncology Nurses"

Copied!
9
0
0

Loading.... (view fulltext now)

Full text

(1)

Citation:Rafie Manesh H, Panjali Z, Khani F, Habibi-Mohraz M, Borhani M. Knowledge and Attitude about Exposure to Cytotoxic Drugs in Oncology Nurses. Archives of Occupational Health. 2019; 3(3): 371-9.

Article History: Received: 13 April 2019; Revised: 19 May 2019; Accepted: 10 June 2019

Copyright: ©2019 The Author(s); Published by Shahid Sadoughi University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1Department of Epidemiology, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran• 2Students' Scientific Research Center, Tehran

University of Medical Sciences, Tehran, Iran• 3Department of Occupational Health Engineering, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences,

Tehran, Iran• 4Nursing, Health and Nursing, Faculty of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran• 5 Department of Occupational Health Engineering,

School of Health, Hamedan University of Medical Sciences, Hamedan, Iran• 6Department of Occupational Health Engineering, Faculty of Health, Iran University of Medical Sciences,

Tehran, Iran• *Corresponding author: Zahra Panjali, Email: [email protected] Tel:+98-912-7971196

Abstract

Background:

Methods:

Results:

Conclusion:

Keywords:

Introduction

(2)
(3)

373

Methods

(4)

Result

Knowledge and attitude

(5)

375

Table 1. Results regarding the questionnaire's reliability and validity

Domain

Internal Repeatability Content validity

Consistency y Transparency Approximations Comprehensiveness

Exposure to cytotoxic drugs 0.841 0.903 0.934 1 1

Attitude regarding exposure and risk 0.681 0.742 0.986 0.986 0.933

Protection and organizational communication in the

workplace 0.801 0.867 0.972 0.986 0.866

Training on cytotoxic drugs 0.727 0.934 0.977 0.988 1

Stress due to handling cytotoxic drugs 0.738 0.919 0.865 0.850 0.666

Hand washing and personal protective equipment 0.672 0.626 0.947 0.832 0.867

Figure 1. Distribution of responses related to attitude towards risks and control measures

Table 2. The frequency of answers to items on exposure and exposure risk

Item Absolutely agree Agree No idea Disagree Absolutely disagree

1. The risk of my exposure to cytotoxic drugs in the hospital is very

low *(5.4)6 (9.0)10 (14.4)16 (50.5)56 (20.7)23

2. I'm afraid to work with cytotoxic drugs or work near these drugs. (21.6)24 32.4)36 (23.4)26 (18.0)20 (4.5)5 3. The safety measures at your workplace are appropriate for reducing

contamination due to the cytotoxic drugs. (7.2)8 (33.3)37 (19.8)22 (26.1)29 (13.5)15 4. My colleagues safely handle cytotoxic drugs (5.4)6 (43.2)48 (21.6)24 (27.9)31 (1.8)2 5. I am sure that I can work safely in all conditions and in all places

where there is a risk of exposure to cytotoxic drugs such as spills, leaks, contaminated urine and vomiting of patients.

(3.6)4 (39.6)44 (18.9)21 (29.7)33 (8.1)9

* Number (percentage)

Table 3. The frequency of answers to items on job stress

Item Absolutely agre Agree No idea Disagree Absolutely disagree

1. This job forces me to work very quickly. (40.5)45 (41.4)46 (11.7)13 (5.4)6 (0.9)1 2. In this job, I'm asked to do a lot of work. (28.8)32 (50.5)56 (10.8)12 (8.1)9 (1.8)2 3. In this job, I have enough time to do my job and handle my duties. (9.0)10 (18.9)21 (20.7)23 (38.7)43 (12.6)14 4. In my current job, there is not much violence, conflict or encounter. (7.2)8 (22.5)25 (36.0)40 (24.3)27 (9.9)11

0 10 20 30 40 50 60 70

Very high High Moderate Low Very Low

Severity of exposure 22.5 35.1 28.8 9.9 3.6

Perceived risk 61.3 30.6 6.3 0.9 0.9

Trying to reduce the risk 33.3 43.2 20.7 0.9 1.8 Successfully to reduce the risk 12.6 23.4 53.2 7.2 3.6

P

er

ce

nt

(6)
(7)

377

(8)

Conclusion

References

1. Workplace Health and Safety Queensland. Guide for handling cytotoxic drugs and related waste. Queensland: office of industrial relation; 2017.

2. Gohari AR, Saeidnia S, Gohari M, Moradi - Afrapoli F, Malmir M, Hadjiakhoondi A, et al. Shrimp Cytotoxicity of Some Medicinal Plants Belongs to Lamiaceae, Asteracea, Rosaceae and Boraginaceae Families. Medicinal Plants. 2009;8(29):87-181. 3. Cornetta T, Padua L, Testa A, Ievolid E, Festa F, Tranfo G, et al.

Molecular biomonitoring of a population of nurses handling antineoplastic drugs. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis. 2008;638(1-2):75-82. 4. Turci R, Sottani C, Ronchi A, Minoia C. Biological monitoring of

hospital personnel occupationally exposed to antineoplastic agents. Toxicology Letters. 2002;134(1-3):57-64.

5. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers. 2014;6(3):1769-92.

6. Connor TH, McDiarmid MA. Preventing Occupational Exposures to Antineoplastic Drugs in Health Care Settings. CA: Cancer Journal for Clinicians. 2006;56(6):354-65.

7. Baker GH. Invited review: Psychological factors and immunity. Psychosomatic Research. 1987;31(1):1-10.

8. Greene MH, Harris EL, Gershenson DM, Malkasian GD, Melton LJ, Dembo AJ, et al. Melphalan may be a more potent leukemogen than cyclophosphamide. Annals of internal medicine. 1986;105(3):360-7.

9. Alert N. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. NIOSH: Department of health and human services CDC; 2004.

10. Donner AL. Possible risk of working with antineoplastic drugs in horizontal laminar flow hoods. American Journal of Health-System Pharmacy. 1978;35(8):900.

11. Ng LM. Possible hazards of handling antineoplastic drugs. Pediatrics. 1970;46(4):648.

12. Mason HJ, Morton J, Garfitt SJ, Iqbal S, Jones K. Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Annals of Occupational Hygiene. 2003;47(8):681-5. 13. Keat CH, Sooaid NS, Yun CY, Sriraman M. Improving

Safety-Related Knowledge, Attitude and Practices of Nurses Handling

(9)

379

journal of cancer care. 2015;24(3):404-10.

15. Pethran A, Schierl R, Hauff K, Grimm C-H, Boos K-S, Nowak D. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. International archives of occupational and environmental health. 2003;76(1):5-10.

16. Ensslin AS, Pethran A, Schierl R, Fruhmann G. Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. International archives of occupational and environmental health. 1994;65(5):339-42. 17. Ensslin AS, Huber R, Pethran A, Römmelt H, Schierl R, Kulka U,

et al. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetics studies. International archives of occupational and environmental health. 1997;70(3):205-8.

18. Minoia C, Turci R, Sottani C, Schiavi A, Perbellini L, Angeleri S, et al. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid communications in mass spectrometry. 1998;12(20):1485-93. 19.Evelo CTA, Bos RP, Peters JGP, Henderson PT. Urinary

cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. International archives of occupational and environmental health. 1986;58(2):151-5.

20. Sessink PJM, Timmersmans JL, Anzion RBM, Bos RP. Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil. Determination of σ-fluoro-ßalanine in urine. Occupational and Environmental Medicine. 1994;36(1):79-83.

21. Mader RM, Rizovski B, Steger GG, Wachter A, Kotz R, Rainer H.

Exposure of oncologic nurses to methotrexate in the treatment of osteosarcoma. Archives of environmental health: An International Journal. 1996;51(4):310-4.

22. Teschke K, Chu W, Hon C-Y. Healthcare Workers and Antineoplastic Drugs: Identifying the Determinants of Exposure and Current Challenges to Reducing Exposure. British Columbia: WorkSafeBC; 2012.

23. Ghasemi E, Janani L, Dehghan Nayeri N, Negarandeh R. Psychometric Properties of Persian Version of the Competency Inventory for Registered Nurse (CIRN). Iran Journal of Nursing. 2014;27(87):1-13.

24. Shirakawa T, Hara T, Hata K, Hata K, Suetsugu K, Kakimoto H, et al. Analysis of a Questionnaire Survey regarding Current Conditions against Exposure to Anticancer Drugs and Reports of Cancer Chemotherapy at Outpatient Departments in Japan. Pharmacology & Pharmacy. 2017;8(05):140.

25. Zhang X, Zheng Q, Lv Y, An M, Zhang Y, Wei Y, et al. Evaluation of adverse health risks associated with antineoplastic drug exposure in nurses at two Chinese hospitals: The effects of implementing a pharmacy intravenous admixture service. American journal of industrial medicine. 2016;59(4):264-73. 26. Sottani C, Porro B, Comelli M, Imbriani M, Minoia C. An analysis

to study trends in occupational exposure to antineoplastic drugs among health care workers. Chromatography B. 2010;878(27):2593-605.

27. Sottani C, Porro B, Imbriani M, Minoia C. Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology letters. 2012;213(1):107-15.

28. Friese CR, Himes-Ferris L, Frasier MN, McCullagh MC, Griggs JJ. Structures and processes of care in ambulatory oncology settings and nurse-reported exposure to chemotherapy. BMJ. 2012;21(9):753–9.

Figure

Table 1. Results regarding the questionnaire's reliability and validity

References

Related documents